Tags Archive Navigation
icon
-
Media ReleaseNovartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME)
-
Media ReleaseEuropean Medicines Agency (EMA) approves safety label update for Novartis Beovu®
-
Media ReleaseNew Phase III analysis demonstrates Novartis Beovu® showed improvement in best-corrected visual acuity in wet AMD patients with early persistent fluid
-
Media ReleaseResults from real-world data and post-hoc analysis of Novartis Beovu® pivotal trials presented at AAO 2020
-
Media ReleaseNovartis reports positive topline results from second Phase III trial of Beovu® in patients with diabetic macular edema
-
Media ReleaseNovartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept
-
Media ReleaseSandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine
-
Media ReleaseNovartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program
-
Media ReleaseNovartis receives EC Approval for Beovu®, a next-generation anti-VEGF treatment for wet AMD, a leading cause of blindness worldwide
-
Media ReleaseUS FDA approves updated Novartis Beovu® label, to include additional safety information
-
Media ReleaseNew Novartis analysis shows wet AMD patients achieved sustained fluid control faster with Beovu® versus aflibercept
-
StoryVisionary: Silke Mader has a vision for the care of premature infants and their parents